Crossmark

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

Crossref DOI link: https://doi.org/10.1186/s12933-021-01346-y

Published Online: 2021-07-23

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Quagliariello, Vincenzo https://orcid.org/0000-0002-4557-5401
De Laurentiis, Michelino

Rea, Domenica

Barbieri, Antonio

Monti, Maria Gaia

Carbone, Andreina

Paccone, Andrea

Altucci, Lucia

Conte, Mariarosaria

Canale, Maria Laura

Botti, Gerardo

Maurea, Nicola
Funding

Funding for this research was provided by:

Ministero della Salute (“Ricerca Corrente” grant from the Italian Ministry of Health. “Cardiotossicità dei trattamenti antineoplastici: identificazione precoce e strategie di cardioprotezione” Project code: M1/5-C)
License Information

Text and Data Mining valid from 2021-07-23

Version of Record valid from 2021-07-23
More Information

Article History

Received: 15 February 2021

Accepted: 16 July 2021

First Online: 23 July 2021

Declarations

:

: Not applicable.

: Not applicable.

: All the authors declare no conflict of interests.

Document is current

Any future updates will be listed below